Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Influx Healthtech IPO
Price Band
₹91.0–96.0
Issue Size
₹58.57 Cr
Lot Size
1,200 shares
Min Investment
₹115,200
GMP
+₹20.0 (20.83%)
Issue Price
₹96.0
Subject to Sauda
₹18200
Paid only if allotted
Influx Healthtech IPO AI Summary
- Influx Healthtech IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹91.0–₹96.0 per share, lot size 1,200 shares (min. investment ₹115,200).
- Subscription window: 18 Jun–20 Jun 2025, listing on 25 Jun 2025.
- Current GMP is +₹20.0 (20.83%), an estimated listing price of ₹116 — unofficial and can change daily.
Influx Healthtech Limited is a healthcare contract manufacturer with a diverse product portfolio and a focus on quality. The company is seeking to raise funds through its IPO to expand its manufacturing capabilities and support its growth in the healthcare sector.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Influx Healthtech IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 20 Jun 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Influx Healthtech IPO Grey Market Premium (GMP) Today
GMP
+₹20.0
GMP %
+20.83%
Est. Listing
₹116.0
Updated: 25 Jul 2026 14:14
About the Company
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries. The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively. Product Portfolio: Tablets, Capsules, and Powders Liquid Orals and Softgels Lozenges, Jellies, and Gummies Oral Dispersible Films (ODFs) Effervescent Tablets and Liquid-Fill Capsules Candies and Gym/Sports Supplements Skin Care and Body Care Products Hair Care and Beard Care Solutions Face Masks and Soaps. Ayurvedic / Herbal formulations Veterinary Feed Supplements Homecare solutions The Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization. As of June 11, 2025, the company has 163 permanent employees on a payroll basis. Competitive Strength Diversified Product Portfolio Diverse Clientele Stringent Quality Assurance/Quality Control Experienced and Qualified Promoters and Management team.
Company Financials (₹ Cr)
As of 2025-03-31
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 70.30 | 41.10 | 28.30 |
| Total Income | 104.99 | 100.10 | 76.07 |
| Profit After Tax | 13.37 | 11.22 | 7.20 |
| NET Worth | 36.15 | 22.87 | 11.65 |
| Reserves and Surplus | 18.00 | 22.85 | 11.63 |
| Total Borrowing | 0.22 | 0.32 | 0.80 |
Key Ratios
EPS
₹7.36
NAV
₹19.91
ROE
36.98%
ROCE
49.17%
RoNW
36.98%
P/B Value
4.82
P/E Ratio
13.04
Market Cap
₹222.24 Cr
PAT Margin
12.75%
Debt/Equity
0.01
Peer Comparison
| Company | NAV | RoNW | EPS Basic | EPS Diluted | P/E (x) |
|---|---|---|---|---|---|
| Influx Healthtech | 19.91 | 36.98% | 7.36 | 7.36 | — |
| Quest Laboratories Limited | 49.92 | 16.58% | 8.28 | 8.28 | 10.38 |
| Sudarshan Pharma Industries Ltd This IPO | 5.3 | 12.45% | 0.66 | 0.66 | 48.28 |
Promoters
Munir Abdul Ganee Chandniwala, Shirin Munir Ahmed Chandniwala and Abdul Ganee Abdul Rasul Chandniwala
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division 22.60 2 Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division 11.59 3 Purchase of Machineries for Homecare and Cosmetic Division 2.76 4 General Corporate Purposes 5.44 5 Issue Expenses 5.83 Total 48.21
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹76.07 Cr in the year ended 31 Mar 2023, increasing to ₹100.10 Cr by 31 Mar 2024, and further rising to ₹104.99 Cr by 31 Mar 2025.
Profit Trend
Profit after tax was ₹7.20 Cr in the year ended 31 Mar 2023, growing to ₹11.22 Cr by 31 Mar 2024, and reaching ₹13.37 Cr by 31 Mar 2025.
Valuation
Influx Healthtech's implied P/E at the issue price of ₹96.0 is approximately 13.04 times its earnings, while peers are trading at P/E ratios ranging from 10.38 to 48.28.
Grey Market Premium, Explained
The grey market premium (GMP) indicates the price at which shares are expected to trade in the grey market before they are officially listed. A positive GMP suggests that investors anticipate a higher listing price compared to the issue price.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their own investment goals and risk appetite, considering the company's growth potential and market conditions.
Who May Want to Wait
Investors who prefer stable returns and are risk-averse may want to avoid IPOs, as they can be subject to significant price fluctuations and market speculation.
IPO Timeline, Explained
The IPO opens for subscription on June 18, 2025, and closes on June 20, 2025. Allotment of shares will be done on June 23, 2025, with shares expected to be listed on June 25, 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when shares are listed on the stock exchange at a price higher than the issue price. However, these gains are not guaranteed and can be influenced by market conditions and investor sentiment.
This evaluation is generated from Influx Healthtech's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Influx Healthtech IPO GMP today?
Influx Healthtech IPO GMP today is +₹20.0 (20.83%), indicating an estimated listing price of ₹116. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Influx Healthtech IPO?
The price band of Influx Healthtech IPO is ₹91.0–₹96.0 per share.
When does Influx Healthtech IPO open and close?
Influx Healthtech IPO opens on 18 June 2025 and closes on 20 June 2025.
When does Influx Healthtech IPO list on the stock exchange?
Influx Healthtech IPO listed on 25 June 2025 at ₹116.0.
What is the lot size for Influx Healthtech IPO?
The lot size for Influx Healthtech IPO is 1200 shares, requiring a minimum investment of ₹115,200.
What is the lot size for this IPO?
The lot size for Influx Healthtech's IPO is 1200 shares.
What is the minimum investment required?
The minimum investment required is ₹115,200.
What is the price band for the IPO?
The price band for the IPO is ₹91.0 to ₹96.0.
When will the shares be listed?
The shares are expected to be listed on June 25, 2025.
What does GMP mean?
GMP stands for grey market premium, which indicates the expected price at which shares may trade in the grey market before the official listing.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
18 Jun 2025
Close
20 Jun 2025
Allotment
23 Jun 2025
Listing
25 Jun 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Influx Healthtech?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.